RP-HPLC method development and validation for determination of eptifibatide acetate in bulk drug substance and pharmaceutical dosage forms

Document Type: Research article

Authors

1 Department of pharmaceutical biotechnology, Faculty of pharmacy, Shahid Beheshti University of medical sciences, Tehran, Iran Students research committee, Faculty of pharmacy, Shahid Beheshti University of medical sciences, Tehran, Iran

2 Department of pharmaceutical biotechnology, Faculty of pharmacy, Shahid Beheshti University of medical sciences, Tehran, Iran

3 Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 -

Abstract

A new, rapid, economical and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method was developed for the determination of eptifibatide acetate, a small synthetic antiplatelet peptide, in bulk drug substance and pharmaceutical dosage forms. The developed method was validated as per of ICH guidelines. The chromatographic separation was achieved isocratically on C18 column (150 x 4.60 mm i.d., 5µm particle size) at ambient temperature using acetonitrile (ACN), water and trifluoroacetic acid (TFA) as mobile phase at flow rate of 1 ml/min and UV detection at 275 nm. Eptifibatide acetate exhibited linearity over the concentration range of 0.15-2 mg/ml (r2=0.997) with limit of detection of 0.15 mg/ml. The accuracy of the method was 96.4-103.8%. The intra-day and inter-day precision were between 0.052% and 0.598%, respectively. The present successfully validated method with excellent selectivity, linearity, sensitivity, precision and accuracy was applicable for the assay of eptifibatide acetate in bulk drug substance and pharmaceutical dosage forms.

Keywords

Main Subjects